Tumour vascular targeting.
It is now accepted that the growth of solid tumours is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process. More recently, it has become apparent that targeted destruction of the established tumour vasculature is another avenue for exciting therapeutic opportunities. In this article, we present evidence that vascular targeting is an effective antitumour strategy in animal models, describe strategies for identifying putative tumour vascular targets and discuss future prospects for vascular targeting in the clinic.
Neri
Dario
D
Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zürich, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich, Switzerland. dario.neri@pharma.ethz.ch
Bicknell
Roy
R
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D019496:Cancer Vaccines; D004195:Disease Models, Animal; D042783:Endothelial Cells; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000503:physiopathology; D009389:Neovascularization, Pathologic
D020533:Angiogenesis Inhibitors; D019496:Cancer Vaccines; D008024:Ligands